医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT

2016年04月26日 PM08:34
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

 

Summary of Events

 
Event     Date and Time     Medium
Release of financial results     May 12th, after the Board Meeting    

Email, Media, Company website, Business Wire

Earnings Call     May 12th , 6.30 PM IST / 9:00 AM EDT     Hosted by the Company

(Details below)

Webcast of Earnings Call     May 12th, 6.30 PM IST / 9.00 AM EDT through May 16th    

URL available on Company’s website, www.drreddys.com

Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

       

Earnings Call

Following the release, the management of the Company will host an Earnings Call to discuss the Company’s financial performance. (Dial In and other details given below)

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through May 16, 2016. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the Earnings Call will also be available on the Company’s website

 
Conference Dial-In Numbers
Primary Number:   +91 22 3960 0616
Secondary Number:   +91 22 6746 5826
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:  

6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada
Accessible from all major carriers except BSNL/MTNL.
3940 3977
Available in – Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune
Accessible from all carriers.

USA: 1 866 746 2133

International Toll Free Number:

UK: 0 808 101 1573

Singapore: 800 101 2045

   

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY; NSE: DRREDDY; BSE: 500124) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005974/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
Kedar
Upadhye, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

Calvin Printer, +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定